KR890005131A - Salts of Organic Germanium Compounds and Pharmaceuticals Comprising the Same - Google Patents

Salts of Organic Germanium Compounds and Pharmaceuticals Comprising the Same Download PDF

Info

Publication number
KR890005131A
KR890005131A KR870009878A KR870009878A KR890005131A KR 890005131 A KR890005131 A KR 890005131A KR 870009878 A KR870009878 A KR 870009878A KR 870009878 A KR870009878 A KR 870009878A KR 890005131 A KR890005131 A KR 890005131A
Authority
KR
South Korea
Prior art keywords
compound
salt
group
basic
organic germanium
Prior art date
Application number
KR870009878A
Other languages
Korean (ko)
Other versions
KR930007994B1 (en
Inventor
고오헤이 미야오
히로시 사또오
노리히로 가끼모도
Original Assignee
고마쯔 야스시
가부시끼가이샤 아사이 게르마늄겐꾸우쇼
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 고마쯔 야스시, 가부시끼가이샤 아사이 게르마늄겐꾸우쇼 filed Critical 고마쯔 야스시
Priority to KR1019870009878A priority Critical patent/KR930007994B1/en
Publication of KR890005131A publication Critical patent/KR890005131A/en
Application granted granted Critical
Publication of KR930007994B1 publication Critical patent/KR930007994B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/30—Germanium compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

내용 없음No content

Description

유기 게르마늄 화합물의 염 및 이를 포함하는 약제Salts of Organic Germanium Compounds and Pharmaceuticals Comprising the Same

본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음As this is a public information case, the full text was not included.

제 1 도는 실시예 1에서 얻어진 화합물의 IR스펙트럼이며,1 is an IR spectrum of the compound obtained in Example 1,

제 2 도는 실시예 2에서 얻어진 화합물의 IR스펙트럼이며,2 is an IR spectrum of the compound obtained in Example 2,

제 3 도는 실시예 5에 있어서의 쥐의 생존그래프이다.3 is a survival graph of rats in Example 5. FIG.

Claims (15)

식(Ⅰ)Formula (Ⅰ) (식중 M은 산소 또는 유황원자이며, R1, R2, R3및 R4는 동일 또는 상이하여도 좋고, 각각 수소원자, 저급 알칼기 또는 아릴기이다.)로 표시되는 유기게르마늄화합물과 염기성기를 갖는 것을 특징으로 하는 화합물과의 염.The organic germanium compound and basic represented by (wherein M is oxygen or sulfur atom, and R 1 , R 2 , R 3 and R 4 may be the same or different, respectively, hydrogen atom, lower alkali group or aryl group). A salt with a compound characterized by having a group. 제 1 항에 있어서, 염기성기를 갖는 화합물이 리조짐인 것을 특징으로 하는 유기게르마늄화합물과 염기성기를 갖는 화합물과의 염.The salt of an organic germanium compound and a compound having a basic group according to claim 1, wherein the compound having a basic group is lysozyme. 제 1 항에 있어서, 염기성기를 갖는 화합물이 염기성 아미노산인 것을 특징으로 하는 유기게르마늄 화합물과 염기성 기를 갖는 화합물과의 염.The salt of an organogermanium compound and a compound having a basic group according to claim 1, wherein the compound having a basic group is a basic amino acid. 제 3 항에 있어서, 염기성기를 갖는 화합물이 L-리신인 것을 특징으로 하는 유기게르마늄 화합물과 염기성기를 갖는 화합물과의 염.4. The salt of an organogermanium compound and a compound having a basic group according to claim 3, wherein the compound having a basic group is L-lysine. 제 1 항에 있어서, M가 산소원자인 것을 특징으로 하는 유기게르마늄화합물과 염기성기를 갖는 화합물과의 염.A salt of an organic germanium compound and a compound having a basic group according to claim 1, wherein M is an oxygen atom. 제 1 항에 있어서, R1, R2, R3및 R4가 수소원자인 것을 특징으로 하는 유기게르마늄화합물과 염기성기를 갖는 화합물과의 염.A salt of an organic germanium compound with a compound having a basic group according to claim 1 , wherein R 1 , R 2 , R 3 and R 4 are hydrogen atoms. 식(Ⅰ)Formula (Ⅰ) (식중 M은 산소 또는 유황원자이며, R1, R2, R3및 R4는 동일 또는 상이하여도 좋고, 각각 수소원자, 저급 알칼기 또는 아릴기이다.)로 표시되는 유기게르마늄화합물과 염기성기를 갖는 화합물과의 염을 주제로 하는 것을 특징으로 하는 생물학적 응답 조절제.The organic germanium compound and basic represented by (wherein M is oxygen or sulfur atom, and R 1 , R 2 , R 3 and R 4 may be the same or different, respectively, hydrogen atom, lower alkali group or aryl group). A biological response modifier characterized in that the salt is a salt with a compound having a group. 제 7 항에 있어서, 염기성기를 갖는 화합물이 리소짐인 것을 특징으로 하는 유기게르마늄화합물과 염기성기를 갖는 화합물과의 염을 주제로 하는 생물학적 응답 조절제.8. The biological response modifier according to claim 7, wherein the compound having a basic group is a lysozyme. The salt of an organic germanium compound and a compound having a basic group is used. 제 7 항에 있어서, M가 산소원자인 것을 특징으로 하는 유기게르마늄화합물과 염기성기를 갖는 화합물과의 염을 주제로 하는 생물학적 응답 조절제.8. The biological response modifier according to claim 7, wherein M is an oxygen atom and a salt of an organic germanium compound and a compound having a basic group. 제 7 항에 있어서, R1, R2, R3및 R4가 수소원자인 것을 특징으로 하는 유기게르마늄화합물과 염기성기를 갖는 화합물과의 염을 주제로 하는 생물학적 응답 조절제.8. The biological response modifier according to claim 7, wherein a salt of an organogermanium compound and a compound having a basic group is characterized in that R 1 , R 2 , R 3 and R 4 are hydrogen atoms. 식(Ⅰ)Formula (Ⅰ) (식중 M은 산소 또는 유황원자이며, R1, R2, R3및 R4는 동일 또는 상이하여도 좋고, 각각 수소원자, 저급 알칼기 또는 아릴기이다.)로 표시되는 유기게르마늄화합물과 염기성기를 갖는 화합물과의 염을 주제로 하는 것을 특징으로 하는 항 종양제.The organic germanium compound and basic represented by (wherein M is oxygen or sulfur atom, and R 1 , R 2 , R 3 and R 4 may be the same or different, respectively, hydrogen atom, lower alkali group or aryl group). An anti-tumor agent, characterized in that the salt with a compound having a group. 제 11 항에 있어서, 염기성기를 갖는 화합물이 염기성 아미노산인 것을 특징으로 하는 유기게르마늄 화합물과 염기성기를 갖는 화합물과의 염을 주제로 하는 항 종양제.12. The antitumor agent according to claim 11, wherein the compound having a basic group is a basic amino acid, and the salt of the organic germanium compound and the compound having a basic group. 제 12 항에 있어서, 염기성기를 갖는 화합물이 L-리신인 것을 특징으로 하는 유기게르마늄화합물과 염기성기를 갖는 화합물과의 염을 주제로 하는 항 종양제.13. The antitumor agent according to claim 12, wherein the compound having a basic group is L-lysine, and the salt of an organic germanium compound and a compound having a basic group. 제 11 항에 있어서, M가 산소원자인 것을 특징으로 하는 유기게르마늄화합물과 염기성기를 갖는 화합물과의 염을 주제로 하는 항 종양제.12. The antitumor agent according to claim 11, wherein M is an oxygen atom, and a salt of an organic germanium compound and a compound having a basic group. 제 11 항에 있어서, R1, R2, R3및 R4가 수소원자인 것을 특징으로 하는 유기게르마늄화합물과 염기성기를 갖는 화합물과의 염을 주제로 하는 항 종양제.12. The antitumor agent according to claim 11, wherein R 1 , R 2 , R 3, and R 4 are hydrogen atoms, and salts of organic germanium compounds with compounds having a basic group. ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.※ Note: The disclosure is based on the initial application.
KR1019870009878A 1987-09-07 1987-09-07 Sald or organogermanium compound and medicine containing the same KR930007994B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1019870009878A KR930007994B1 (en) 1987-09-07 1987-09-07 Sald or organogermanium compound and medicine containing the same

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1019870009878A KR930007994B1 (en) 1987-09-07 1987-09-07 Sald or organogermanium compound and medicine containing the same

Publications (2)

Publication Number Publication Date
KR890005131A true KR890005131A (en) 1989-05-13
KR930007994B1 KR930007994B1 (en) 1993-08-25

Family

ID=19264299

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019870009878A KR930007994B1 (en) 1987-09-07 1987-09-07 Sald or organogermanium compound and medicine containing the same

Country Status (1)

Country Link
KR (1) KR930007994B1 (en)

Also Published As

Publication number Publication date
KR930007994B1 (en) 1993-08-25

Similar Documents

Publication Publication Date Title
KR960704919A (en) NOVEL PEPTIDE DERIVATIVE
KR870008879A (en) Manufacturing method of thiazine
KR860001110A (en) Preparation of Antibacterial Agent II
KR950003267A (en) Process for preparing amino-substituted thioether
KR890002198A (en) Organosilicon compounds
KR850006415A (en) Manufacturing method of antibacterial agent
KR890005131A (en) Salts of Organic Germanium Compounds and Pharmaceuticals Comprising the Same
KR880001744A (en) Radiation Resistant Polyolefin Composition
KR850002974A (en) Method for preparing sulfenamide derivative
KR850004742A (en) Preparation of Substituted Tetrazole
KR840007656A (en) Insecticide composition
KR880005095A (en) Method for preparing 2,4-diamino-3-oxy-pyrimidine derivative
KR880001628A (en) Synthesis of Bicyclic Aromatic Sulfonyl Chloride
KR830010075A (en) Method for preparing compound having peripheral vasodilating action
KR850002978A (en) Chemical method
KR860008996A (en) Method for preparing guanidino thiazole compound
KR840000504A (en) Method for preparing N-phenylpyrazole derivatives
KR910011884A (en) Method for preparing amino glycoside antibiotic
SE8105338L (en) NEW SET TO MAKE APOVINCAMIC ACID ESTERS
KR920018019A (en) N-benzoyl-C- thiophenoxyimidoyl chloride derivative and preparation method thereof
KR920021560A (en) Process for the preparation of 7-amino-3-azidomethyl-3-cepem-4-carboxylic acid
KR860004021A (en) Process for preparing ethyleneimine derivative
KR860002473A (en) Method for preparing 4-methyl-5-thioformamidinomethylimidazole dihydrochloride
KR830004335A (en) Method for preparing 6α, 9α-difluoro-16-methyl-prednisolone-17,21-diester
KR890009949A (en) Method for producing dialkyldithiophosphate zinc salt

Legal Events

Date Code Title Description
A201 Request for examination
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20010804

Year of fee payment: 9

LAPS Lapse due to unpaid annual fee